Signaling through GITR drives a high-avidity CD8+ T-cell response to tumor antigens, increases effector T-cell proliferation via expression of cytokines IL-2 and IFN-γ, and reduces the suppressive function of Tregs [26,27,28]. The gene discussed is CD8A; the disease is neoplasm.